Patients diagnosed with deep vein thrombosis (DVT) and treated with rivaroxaban (Xarelto) were admitted to the hospital less frequently than those treated with the standard treatment of low-molecular-weight heparin (LMWH) and warfarin, according to real-world data presented at the Hospital Medicine 2015 Congress.
Patients diagnosed with deep vein thrombosis (DVT) and treated with rivaroxaban (Xarelto) were admitted to the hospital less frequently than those treated with the standard treatment of low-molecular-weight heparin (LMWH) and warfarin, according to real-world data presented at the Hospital Medicine 2015 Congress.
This reduction in hospital admissions with rivaroxaban resulted in significant cost savings with no difference in subsequent hospital visits versus the standard of care.
Related:Rivaroxaban alternative option for elderly
The observational study included 134 people treated with rivaroxaban and 536 patients treated with LMWH and warfarin (prior to the approval of Xarelto). A retrospective claims analysis was conducted using the Truven MarketScan Hospital Drug Database from January 2011 to December 2013. Adult patients with a primary diagnosis of DVT treated with rivaroxaban or LMWH bridged to warfarin during the first day of an evaluation at a hospital were identified. Based on propensity-score methods historical LMWH/warfarin patients (ie, patients who received LMWH/warfarin before the approval of rivaroxaban) were matched 4:1 to rivaroxaban patients, and the rates of hospitalization were compared.
Researchers found:
Dr Merli“This study adds to existing research demonstrating the value that [rivaroxaban] brings to hospitals, doctors and patients across multiple indications,” said study lead author Geno Merli, MD, professor of medicine and surgery, co-director of the Jefferson Vascular Center, Thomas Jefferson University Hospital, Philadelphia. ”[Rivaroxaban] has been shown to reduce hospital length of stay [LOS], and now hospital admissions, as compared to traditional treatment. This often results in costs savings.
Related: Oral anticoagulation may not help all AF patients
“A single once-daily agent is effective in treating DVT effectively and safely,” said Dr Merli. “Selecting 1 or 2 of the new agents in a field of 4 agents would control costs. Outpatient treatment of VTE reduces cost as well as unnecessary admissions.”
The study was sponsored by Janssen.
Read next: VTE treatment regimens have similar outcomes
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More